N/A
N=4,695
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
COVID-19 · Myocardial Reperfusion Injury · Cardiovascular Diseases
Bottom Line
View on ClinicalTrials.gov: NCT04397939 ↗Enrolled (actual)
4,695
Serious AEs
—
Results posted
Mar 2024
Primary outcome: Primary: Number of Death — 417; 137; 552 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Death |
417; 137; 552 | — |
| SECONDARY Number of Participants With Pulmonary Embolism |
32; 4; 22 | — |
| SECONDARY Number of Participants With Acute Kidney Injury |
99; 30; 107 | — |
| SECONDARY Number of Admissions to the Intensive Care |
393; 64; 325 | — |
Summary
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.
Eligibility Criteria
Inclusion Criteria
- Laboratory confirmed COVID-19
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT04397939). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.